Detail page

Knowledge Web

Person

Marc Remke (1981-)

Arzt

Name	Marc Remke
Time	1981- (Date of birth and death)
Place	Bonn-Duisdorf (Geburtsort) Deutschland
Profession	Arzt (characteristic profession)
Variant	Marc Karl Heinrich Remke Marc K. H. Remke
Further information	Diss. Medizinische Fakultät an der Universität Heidelberg; Pädiatrische Hämatologie und Onkologie am Zentrum für Kinder- und Jugendmedizin der Universität Heidelberg
Record type	Person
GND-Identifier	140368787
Record ID	140368787
Involved in show all A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification The EIF4EBP1 gene encoding 4EBP1 is transcriptionally upregulated by MYC and linked to shorter survival in medulloblastoma Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT) An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT) Identifikation neuer therapeutischer Ansätze für hochmaligne Gliome im Kindes- und Erwachsenenalter Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47- induced macrophage phagocytosis via NF- kB- TGM2 driven tumor inflammation A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines Drug screening to identify targeted therapies in atypical teratoid/rhabdoid tumors Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells CD155 is a putative therapeutic target in medulloblastoma Primary cilia contribute to the aggressiveness of atypical teratoid/rhabdoid tumors Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors Structural damage burden and hypertrophic olivary degeneration in pediatric postoperative cerebellar mutism syndrome Progenitor cells derived from gene‐engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors Circular RNA profiling distinguishes medulloblastoma groups and shows aberrant RMST overexpression in WNT medulloblastoma Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma KLF4 K409Q –mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment Proteome‐Wide Survey of Cysteine Oxidation by Using a Norbornene Probe † The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells Infant medulloblastoma — learning new lessons from old strata Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response Abstracts of the 52nd Workshop for Pediatric Research : Frankfurt, Germany. 27-28 October 2016 MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties Risk stratification of childhood medulloblastoma in the molecular era: the current consensus MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties New brain tumor entities emerge from molecular classification of CNS-PNETs Integrated genomics elucidates relative spatial homogeneity of embryonal brain tumors WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma G-protein coupled receptor expression patterns delineate medulloblastoma subgroups Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas Dissecting the genomic complexity underlying medulloblastoma Biological and clinical heterogeneity of MYCN-amplified medulloblastoma Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes High resolution genomic profiling identifies prognostic DNA copy-number aberrations and novel oncogenic pathways in pediatric neoplasias

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Marc Remke (1981-)

A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification

The EIF4EBP1 gene encoding 4EBP1 is transcriptionally upregulated by MYC and linked to shorter survival in medulloblastoma

Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models

Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology

An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT)

An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT)

Identifikation neuer therapeutischer Ansätze für hochmaligne Gliome im Kindes- und Erwachsenenalter

Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47- induced macrophage phagocytosis via NF- kB- TGM2 driven tumor inflammation

A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases

mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism

Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines

Drug screening to identify targeted therapies in atypical teratoid/rhabdoid tumors

Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer

The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures

The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma

Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma

Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

CD155 is a putative therapeutic target in medulloblastoma

Primary cilia contribute to the aggressiveness of atypical teratoid/rhabdoid tumors

Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer

The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors

Structural damage burden and hypertrophic olivary degeneration in pediatric postoperative cerebellar mutism syndrome

Progenitor cells derived from gene‐engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology

The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors

Circular RNA profiling distinguishes medulloblastoma groups and shows aberrant RMST overexpression in WNT medulloblastoma

Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses

The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma

KLF4 K409Q –mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment

Proteome‐Wide Survey of Cysteine Oxidation by Using a Norbornene Probe †

The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells

Infant medulloblastoma — learning new lessons from old strata

Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response

Abstracts of the 52nd Workshop for Pediatric Research : Frankfurt, Germany. 27-28 October 2016

MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus

MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties

New brain tumor entities emerge from molecular classification of CNS-PNETs

Integrated genomics elucidates relative spatial homogeneity of embryonal brain tumors

WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma

CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity

Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion

Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity

Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma

G-protein coupled receptor expression patterns delineate medulloblastoma subgroups

Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma

Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma

DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

Dissecting the genomic complexity underlying medulloblastoma

Biological and clinical heterogeneity of MYCN-amplified medulloblastoma

Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma

Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes

High resolution genomic profiling identifies prognostic DNA copy-number aberrations and novel oncogenic pathways in pediatric neoplasias